Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development Acorda Therapeutics Inc Adamed Sp z oo Avineuro Pharmaceuticals Inc Celon Pharma SA H. Lundbeck AS Reviva Pharmaceuticals Inc Suven Life Sciences Ltd Teva Pharmaceutical Industries Ltd 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles ADN-1184 - Drug Profile Product Description Mechanism Of Action R&D Progress ADN-2013 - Drug Profile Product Description Mechanism Of Action R&D Progress ADN-3662 - Drug Profile Product Description Mechanism Of Action R&D Progress AV-3208 - Drug Profile Product Description Mechanism Of Action R&D Progress AVN-101 - Drug Profile Product Description Mechanism Of Action R&D Progress AVN-211 - Drug Profile Product Description Mechanism Of Action R&D Progress AVN-3205 - Drug Profile Product Description Mechanism Of Action R&D Progress AVN-322 - Drug Profile Product Description Mechanism Of Action R&D Progress AVN-492 - Drug Profile Product Description Mechanism Of Action R&D Progress landipirdine - Drug Profile Product Description Mechanism Of Action R&D Progress LuAF-35700 - Drug Profile Product Description Mechanism Of Action R&D Progress RP-5063 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress SUVN-501 - Drug Profile Product Description Mechanism Of Action R&D Progress SUVN-502 - Drug Profile Product Description Mechanism Of Action R&D Progress SUVN-507 - Drug Profile Product Description Mechanism Of Action R&D Progress SUVN-512 - Drug Profile Product Description Mechanism Of Action R&D Progress 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones Featured News & Press Releases Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders drug candidate SUVN-502 at Neuroscience 2017 at Washington DC Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH) May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016 Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s Disease Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease Jul 30, 2014: Biotie updates outlook on SYN120 Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of Treatment of Parkinson's Disease Jul 08, 2014: Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Disease Dementia Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for RP5063 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Acorda Therapeutics Inc, H1 2018 Pipeline by Adamed Sp z oo, H1 2018 Pipeline by Avineuro Pharmaceuticals Inc, H1 2018 Pipeline by Celon Pharma SA, H1 2018 Pipeline by H. Lundbeck AS, H1 2018 Pipeline by Reviva Pharmaceuticals Inc, H1 2018 Pipeline by Suven Life Sciences Ltd, H1 2018 Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Dormant Products, H1 2018 (Contd..2), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administrations, H1 2018 Number of Products by Stage and Molecule Types, H1 2018